UniProt ID | CSK22_HUMAN | |
---|---|---|
UniProt AC | P19784 | |
Protein Name | Casein kinase II subunit alpha' | |
Gene Name | CSNK2A2 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 350 | |
Subcellular Localization | ||
Protein Description | Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. May act as a regulatory node which integrates and coordinates numerous signals leading to an appropriate cellular response. During mitosis, functions as a component of the p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in response to spindle damage. Also required for p53/TP53-mediated apoptosis, phosphorylating 'Ser-392' of p53/TP53 following UV irradiation. Can also negatively regulate apoptosis. Phosphorylates the caspases CASP9 and CASP2 and the apoptotic regulator NOL3. Phosphorylation protects CASP9 from cleavage and activation by CASP8, and inhibits the dimerization of CASP2 and activation of CASP8. Regulates transcription by direct phosphorylation of RNA polymerases I, II, III and IV. Also phosphorylates and regulates numerous transcription factors including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, SRF, MAX, JUN, FOS, MYC and MYB. Phosphorylates Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for chaperone function. Regulates Wnt signaling by phosphorylating CTNNB1 and the transcription factor LEF1. Acts as an ectokinase that phosphorylates several extracellular proteins. During viral infection, phosphorylates various proteins involved in the viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV.. | |
Protein Sequence | MPGPAAGSRARVYAEVNSLRSREYWDYEAHVPSWGNQDDYQLVRKLGRGKYSEVFEAINITNNERVVVKILKPVKKKKIKREVKILENLRGGTNIIKLIDTVKDPVSKTPALVFEYINNTDFKQLYQILTDFDIRFYMYELLKALDYCHSKGIMHRDVKPHNVMIDHQQKKLRLIDWGLAEFYHPAQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRREPFFHGQDNYDQLVRIAKVLGTEELYGYLKKYHIDLDPHFNDILGQHSRKRWENFIHSENRHLVSPEALDLLDKLLRYDHQQRLTAKEAMEHPYFYPVVKEQSQPCADNAVLSSGLTAAR | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
13 | Nitration | AGSRARVYAEVNSLR CCCHHEEEEEHHHHH | 7.47 | - | |
13 | Phosphorylation | AGSRARVYAEVNSLR CCCHHEEEEEHHHHH | 7.47 | 28796482 | |
18 | Phosphorylation | RVYAEVNSLRSREYW EEEEEHHHHHCCCCC | 30.27 | 28176443 | |
21 | Phosphorylation | AEVNSLRSREYWDYE EEHHHHHCCCCCCEE | 34.45 | 17192257 | |
24 | Phosphorylation | NSLRSREYWDYEAHV HHHHCCCCCCEEECC | 11.50 | 28796482 | |
27 | Phosphorylation | RSREYWDYEAHVPSW HCCCCCCEEECCCCC | 10.81 | 28796482 | |
33 | Ubiquitination | DYEAHVPSWGNQDDY CEEECCCCCCCHHHH | 46.67 | 24816145 | |
45 | Ubiquitination | DDYQLVRKLGRGKYS HHHHHHHHHCCCCHH | 48.06 | 22817900 | |
50 | Ubiquitination | VRKLGRGKYSEVFEA HHHHCCCCHHHHHHE | 44.22 | 22817900 | |
50 | Acetylation | VRKLGRGKYSEVFEA HHHHCCCCHHHHHHE | 44.22 | 25953088 | |
51 | Phosphorylation | RKLGRGKYSEVFEAI HHHCCCCHHHHHHEE | 16.94 | 20090780 | |
52 | Phosphorylation | KLGRGKYSEVFEAIN HHCCCCHHHHHHEEE | 30.67 | 20071362 | |
62 | Ubiquitination | FEAINITNNERVVVK HHEEECCCCCEEEEE | 44.56 | 24816145 | |
69 | Ubiquitination | NNERVVVKILKPVKK CCCEEEEEEEHHCCH | 30.61 | - | |
72 | Ubiquitination | RVVVKILKPVKKKKI EEEEEEEHHCCHHHC | 51.76 | - | |
75 | Acetylation | VKILKPVKKKKIKRE EEEEHHCCHHHCHHH | 68.36 | 25953088 | |
84 | Ubiquitination | KKIKREVKILENLRG HHCHHHHHHHHHCCC | 36.50 | 29967540 | |
90 | Methylation | VKILENLRGGTNIIK HHHHHHCCCCCEEHH | 53.75 | - | |
97 | Acetylation | RGGTNIIKLIDTVKD CCCCEEHHHHHHCCC | 35.28 | 19608861 | |
103 | Malonylation | IKLIDTVKDPVSKTP HHHHHHCCCCCCCCC | 59.41 | 26320211 | |
103 | Acetylation | IKLIDTVKDPVSKTP HHHHHHCCCCCCCCC | 59.41 | 23236377 | |
103 | Succinylation | IKLIDTVKDPVSKTP HHHHHHCCCCCCCCC | 59.41 | 23954790 | |
111 | Ubiquitination | DPVSKTPALVFEYIN CCCCCCCCHHEEECC | 22.91 | 22817900 | |
116 | Phosphorylation | TPALVFEYINNTDFK CCCHHEEECCCCCHH | 9.48 | - | |
119 | Ubiquitination | LVFEYINNTDFKQLY HHEEECCCCCHHHHH | 31.31 | 24816145 | |
123 | Ubiquitination | YINNTDFKQLYQILT ECCCCCHHHHHHHHH | 42.05 | 22817900 | |
124 | Ubiquitination | INNTDFKQLYQILTD CCCCCHHHHHHHHHH | 45.45 | 22817900 | |
140 | Ubiquitination | DIRFYMYELLKALDY HHHHHHHHHHHHHHH | 30.97 | 22817900 | |
152 | Ubiquitination | LDYCHSKGIMHRDVK HHHHHHCCCCCCCCC | 26.01 | 22817900 | |
153 | Ubiquitination | DYCHSKGIMHRDVKP HHHHHCCCCCCCCCC | 2.12 | 22817900 | |
159 | Ubiquitination | GIMHRDVKPHNVMID CCCCCCCCCCCEEEE | 44.86 | 29967540 | |
159 | Acetylation | GIMHRDVKPHNVMID CCCCCCCCCCCEEEE | 44.86 | 26051181 | |
164 | Sulfoxidation | DVKPHNVMIDHQQKK CCCCCCEEEECCHHH | 3.46 | 30846556 | |
170 | Ubiquitination | VMIDHQQKKLRLIDW EEEECCHHHHHHHHH | 47.40 | 24816145 | |
180 | Ubiquitination | RLIDWGLAEFYHPAQ HHHHHHHHHHCCHHH | 10.83 | 27667366 | |
193 | Ubiquitination | AQEYNVRVASRYFKG HHHCCCEEEHHHCCC | 5.03 | 24816145 | |
195 | Phosphorylation | EYNVRVASRYFKGPE HCCCEEEHHHCCCCE | 25.34 | 28355574 | |
197 | Ubiquitination | NVRVASRYFKGPELL CCEEEHHHCCCCEEE | 13.72 | 22817900 | |
197 | Phosphorylation | NVRVASRYFKGPELL CCEEEHHHCCCCEEE | 13.72 | 23186163 | |
209 | Ubiquitination | ELLVDYQMYDYSLDM EEEEEEECCCCCHHH | 1.93 | 22817900 | |
210 | Ubiquitination | LLVDYQMYDYSLDMW EEEEEECCCCCHHHH | 9.01 | 22817900 | |
210 | Phosphorylation | LLVDYQMYDYSLDMW EEEEEECCCCCHHHH | 9.01 | - | |
222 | Ubiquitination | DMWSLGCMLASMIFR HHHHHHHHHHHHHHH | 3.12 | 24816145 | |
240 | Phosphorylation | FFHGQDNYDQLVRIA CCCCCCCHHHHHHHH | 17.23 | 22817900 | |
248 | Ubiquitination | DQLVRIAKVLGTEEL HHHHHHHHHHCHHHH | 35.30 | 22817900 | |
256 | Phosphorylation | VLGTEELYGYLKKYH HHCHHHHHHHHHHHC | 13.65 | 12628006 | |
260 | Acetylation | EELYGYLKKYHIDLD HHHHHHHHHHCCCCC | 42.68 | 25953088 | |
260 | Ubiquitination | EELYGYLKKYHIDLD HHHHHHHHHHCCCCC | 42.68 | 21906983 | |
261 | Ubiquitination | ELYGYLKKYHIDLDP HHHHHHHHHCCCCCH | 39.19 | 33845483 | |
266 | Ubiquitination | LKKYHIDLDPHFNDI HHHHCCCCCHHHHHH | 12.49 | 27667366 | |
279 | Ubiquitination | DILGQHSRKRWENFI HHCCHHHHHHHHHHC | 30.36 | 24816145 | |
280 | Ubiquitination | ILGQHSRKRWENFIH HCCHHHHHHHHHHCC | 65.95 | - | |
280 | Malonylation | ILGQHSRKRWENFIH HCCHHHHHHHHHHCC | 65.95 | 26320211 | |
288 | Phosphorylation | RWENFIHSENRHLVS HHHHHCCCCCCCCCC | 31.58 | 17192257 | |
304 | Ubiquitination | EALDLLDKLLRYDHQ HHHHHHHHHHCCCHH | 49.76 | - | |
308 | Phosphorylation | LLDKLLRYDHQQRLT HHHHHHCCCHHHCCC | 20.11 | 26074081 | |
315 | Phosphorylation | YDHQQRLTAKEAMEH CCHHHCCCHHHHHHC | 37.56 | 26074081 | |
317 | Ubiquitination | HQQRLTAKEAMEHPY HHHCCCHHHHHHCCC | 40.55 | 27667366 | |
324 | Phosphorylation | KEAMEHPYFYPVVKE HHHHHCCCCHHHCCC | 20.04 | 26074081 | |
326 | Phosphorylation | AMEHPYFYPVVKEQS HHHCCCCHHHCCCCC | 6.83 | 26074081 | |
330 | Ubiquitination | PYFYPVVKEQSQPCA CCCHHHCCCCCCCCC | 50.71 | 32015554 | |
330 | Acetylation | PYFYPVVKEQSQPCA CCCHHHCCCCCCCCC | 50.71 | 26051181 | |
333 | Phosphorylation | YPVVKEQSQPCADNA HHHCCCCCCCCCCCC | 36.86 | 25159151 | |
343 | Phosphorylation | CADNAVLSSGLTAAR CCCCCHHCCCCCCCC | 18.76 | 27050516 | |
347 | O-linked_Glycosylation | AVLSSGLTAAR---- CHHCCCCCCCC---- | 23.07 | 28657654 |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of CSK22_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of CSK22_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-97, AND MASS SPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-13; SER-18; SER-21;TYR-240; SER-288 AND SER-343, AND MASS SPECTROMETRY. | |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18; SER-21 AND SER-288,AND MASS SPECTROMETRY. |